Chief Medical Officer of Hungary

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Retrieved on: 
Wednesday, November 1, 2023
Chief Medical Officer of Hungary, Pharmacist, Pharmaceutical industry, MD

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023.
  • The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s.
  • Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
  • Presenter: Matthew Davis, MD, RPh., Chief Operating Officer and Chief Medical Officer, Tiziana Life Sciences
    BIO-Europe convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry's largest gathering of biopharma professionals in Europe.

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, June 29, 2023
Empyrean, Psilocybin, BioImpacts, Toronto Stock Exchange, PD, Glenmark Pharmaceuticals, D.O, Reunion, Pharmacovigilance, Biotechnology, Scientific Research and Experimental Development Tax Credit Program, Calendar, Woman, Arrangement, Bristol Myers Squibb, FAPA, Trial of the century, ASCP, Eli Lilly, Spinout, Annual general meeting, Drug discovery, TSX, Chief Medical Officer of Hungary, Johnson & Johnson, Research, Society, MPM, Scientific method, Pharmaceutical industry, Cryptocurrency

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Shareholders will be entitled to receive US$1.12 in cash for each share held immediately prior to the effective time of the take-private transaction.
  • The transaction is currently contemplated to close in the third calendar quarter of 2023, subject to satisfaction of certain closing conditions.
  • On April 3, 2023, Reunion announced that it appointed seasoned pharmaceutical executive, Fred Grossman, D.O., FAPA, to its Board of Directors.
  • Drug Effect Questionnaire and Mystical Effect Questionnaire scores observed at these dose levels indicate the potential for therapeutic effect.